Scarica l'app Stockscreener
0.40
6.64%
0.0249
Dopo l'orario di chiusura:
.36
-0.04
-10.00%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.3751
Aprire:
$0.3738
Volume 24 ore:
613.67K
Relative Volume:
0.29
Capitalizzazione di mercato:
$13.89M
Reddito:
$1.50M
Utile/perdita netta:
$-64.59M
Rapporto P/E:
-0.2395
EPS:
-1.67
Flusso di cassa netto:
$-55.17M
1 W Prestazione:
+19.37%
1M Prestazione:
+23.46%
6M Prestazione:
-86.67%
1 anno Prestazione:
-85.87%
Intervallo 1D:
$0.3386
$0.40
Intervallo di 1 settimana:
$0.3301
$0.40
Portata 52W:
$0.2223
$4.79
Leap Therapeutics Inc Stock (LPTX) Company Profile
Nome
Leap Therapeutics Inc
Settore
Industria
Telefono
617 252 4343
Indirizzo
47 THORNDIKE STREET, CAMBRIDGE, MA
Confronta LPTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LPTX
Leap Therapeutics Inc
|
0.40 | 13.89M | 1.50M | -64.59M | -55.17M | -1.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
432.00 | 115.57B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
574.16 | 60.30B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
542.47 | 37.56B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
266.86 | 35.18B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
224.73 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
Leap Therapeutics Inc Stock (LPTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-29 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-01-29 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-06-28 | Iniziato | Rodman & Renshaw | Buy |
| 2021-10-04 | Iniziato | Mizuho | Buy |
| 2021-06-04 | Ripresa | Robert W. Baird | Outperform |
| 2020-06-29 | Iniziato | Piper Sandler | Overweight |
| 2020-02-11 | Iniziato | Robert W. Baird | Outperform |
| 2019-11-15 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2019-09-13 | Ripresa | Raymond James | Outperform |
| 2017-03-07 | Iniziato | Ladenburg Thalmann | Buy |
Mostra tutto
Leap Therapeutics Inc Borsa (LPTX) Ultime notizie
Metastatic Colorectal Cancer Clinical Trial Pipeline Accelerates as 150+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight - GlobeNewswire Inc.
Cash-strapped Cambridge cancer biotech halves workforce - The Business Journals
Leap Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Leap Therapeutics Q1 Net Income USD -15.435 Million - marketscreener.com
Leap Therapeutics Reports First Quarter 2025 Financial Results | - GuruFocus
Leap Therapeutics Reports First Quarter 2025 Financial Results - Citizen Tribune
Leap TherapeuticsAnnounces 50% Workforce Reduction In Strategic RestructuringSEC Filing - marketscreener.com
Leap Therapeutics, Inc. (LPTX) Q1 Loss Beats Estimates - Nasdaq
LEAP THERAPEUTICS, INC. SEC 10-Q Report - TradingView
Leap Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Purple Biotech Appoints Shai Lankry as Chief Financial Officer - The Manila Times
Leap Therapeutics (LPTX) Expected to Announce Quarterly Earnings on Monday - Defense World
Leap Therapeutics Inc expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Closing Bell Recap: Leap Therapeutics Inc (LPTX) Ends at 0.34, Reflecting a -12.39 Downturn - DWinneX
LPTX’s Market Whiplash: -85.46% YTD Decline, 37.04% Rise in 30 Days - investchronicle.com
75,800 Shares in Leap Therapeutics, Inc. (NASDAQ:LPTX) Acquired by LPL Financial LLC - Defense World
Quarterly Snapshot: Quick and Current Ratios for Leap Therapeutics Inc (LPTX) - DWinneX
Leap Therapeutics to Present Preclinical Data of FL-501, a Novel - GuruFocus
Novel Cancer Cachexia Drug FL-501 Shows 3X Better Half-Life in Preclinical Data | LPTX Stock News - Stock Titan
Metastatic Colorectal Cancer Market Poised for Expansion Across the 7MM During the Forecast Period (2025-2034) as Breakthrough Therapies Gain Traction | DelveInsight - PR Newswire UK
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatam - GuruFocus
Leap Therapeutics to Host Virtual KOL Event to Discuss Sirexatamab (DKN-01) in Second-line Patients with Advanced Microsatellite Stable Colorectal Cancer | LPTX Stock News - GuruFocus
Leading Oncologist Reveals Game-Changing Phase 2 Results for Advanced Colorectal Cancer Treatment - Stock Titan
Leap Therapeutics stock hits 52-week low at $0.28 amid downturn - Investing.com Canada
Leap Therapeutics stock hits 52-week low at $0.28 amid downturn By Investing.com - Investing.com South Africa
BlossomHill Therapeutics to Present the Design and Discovery of BH-30643, the Company’s OMNI-EGFR™ Inhibitor, at the 2025 AACR Annual Meeting - Business Wire
HC Wainwright Expects Reduced Earnings for Leap Therapeutics - Defense World
Leap Therapeutics (NASDAQ:LPTX) Earns Neutral Rating from HC Wainwright - The AM Reporter
HC Wainwright Reiterates Neutral Rating for Leap Therapeutics (NASDAQ:LPTX) - Defense World
H.C. Wainwright maintains neutral on Leap Therapeutics stock By Investing.com - Investing.com Canada
12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga
Leap reports progress in colorectal cancer study By Investing.com - Investing.com South Africa
Driving the Future of Healthcare HIT, OSRH, THTX, LPTX, CSDX, Innovations in Health Insurance, Virtual Care, Oncology, and Chronic Disease Treatment - Financial Content
Micro Cap Soars Following Preliminary Data Update - The Globe and Mail
Penny Stock Leap Therapeutics Unveils Positive Data From Experimental Combo Therapy For Colorectal Cancer - Yahoo
LEAP THERAPEUTICS Earnings Results: $LPTX Reports Quarterly Earnings - Nasdaq
Leap Therapeutics Says New Data Show Sirexatamab Improves Survival in Colorectal Cancer Trial - MarketScreener
Leap Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Leap Therapeutics Reports Positive Updated Data from Sirexatamab Colorectal Cancer Study - MarketScreener
Leap Therapeutics Reports Positive DeFianCe Phase 2 Data Of Sirexatamab In Colorectal Cancer - Nasdaq
Leap Therapeutics Reports Fourth Quarter And FY 2024 Results - Marketscreener.com
Leap reports progress in colorectal cancer study - Investing.com India
Breakthrough: Leap's Colorectal Cancer Drug Delivers 32% Higher Response Rate in Latest Trial - Stock Titan
Tobacco Control Has Saved Nearly 4 Millions Lives, Study Estimates - 69News WFMZ-TV
Leap Therapeutics stock hits 52-week low at $0.39 - Investing.com
Leap Therapeutics stock hits 52-week low at $0.39 By Investing.com - Investing.com UK
LEAP THERAPEUTICS Earnings Preview: Recent $LPTX Insider Trading, Hedge Fund Activity, and More - Nasdaq
Leap Therapeutics stock hits 52-week low at $0.4 amid sharp decline - Investing.com India
Leap Therapeutics stock hits 52-week low at $0.4 amid sharp decline By Investing.com - Investing.com South Africa
Atossa Therapeutics plans to develop durg to treat advanced breast cancer, talks with FDA on other uses - Marketscreener.com
Sun Pharma's Strategic Leap: Acquiring Checkpoint Therapeutics - Devdiscourse
Leap Therapeutics Inc Azioni (LPTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):